Isolate RNA and DNA-based therapeutics / metabolites from biological fluids and tissues in less time with Clarity OTX solid phase extraction (SPE) and buffer products.
U.S. Patent No. 7,119,145
Brand Clarity (SPE) |
Recommended Use Extraction of RNA and DNA-based therapeutics/metabolites from biological fluids and tissues |
Oligo types | Sample Types |
---|---|
DNA | Plasma |
Aptamers | Serum |
RNAi/siRNA | Urine |
Thioates | Tears |
Lipid-conjugates | Saliva |
Liposome encapsulated |
Tissue |
Sample Pre-Treatment | |
---|---|
Tissue |
|
Biological Fluids |
|
Column:
Clarity 3 µm Oligo-RP C18
|
Dimension:
50 x 4.6 mm
|
Part No.:
00B-4441-E0
|
Mobile Phase:
A: 50 mM TEAA, pH 7.5 / 5 % Acetonitrile
B: Methanol |
Gradient:
A/B (90:10) to A/B (40:60) in 20 min
|
Flow Rate:
1 mL/ min
|
Detection:
UV @ 260 nm
|
Sample:
25nt DNA oligonucleotide
|
The level of MS sensitivity is highly linked to the MS instrument and HPLC mobile phase used. Contact Phenomenex for questions about sensitivity levels achieved with Clarity OTX on various instruments with specific mobile phases.